Sign In
Buy MG
$17.60
-0.440 (-2.44%)
At Close: Jun 03, 2026
What If Mistras Isn't As Broken As It Looks?
08:38am, Wednesday, 09'th Jul 2025
Mistras Group has underperformed since IPO, but now trades at a deep discount with significant upside potential based on EV/EBITDA and EV/S multiples. Short-term headwinds from Oil & Gas weakness and
MISTRAS Group Names Cody Elliott Vice President of Pipeline Data Solutions
09:00am, Wednesday, 25'th Jun 2025
PRINCETON JUNCTION, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE), a global leader in technology-enabled industrial asset integrity solutions, today announced the appointment
Mistras Group, Inc. (MG) Q1 2025 Earnings Call Transcript
09:54am, Friday, 09'th May 2025
Mistras Group, Inc. (NYSE:MG ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Corporate Participants Thomas Tobolski - Treasurer Natalia Shuman - President and Chief Executive Officer Edward
Mistras (MG) Reports Q1 Loss, Lags Revenue Estimates
08:35pm, Wednesday, 07'th May 2025
Mistras (MG) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.16. This compares to earnings of $0.07 per share a year ago.
MISTRAS Announces First Quarter 2025 Results
05:55pm, Wednesday, 07'th May 2025
Reinvigorated senior leadership with recently on-boarded, high-caliber positions with proven industry experience, to focus on delivering value to customers
MISTRAS Group Announces Conference Call to Discuss First Quarter Results on May 8, 2025
04:35pm, Monday, 05'th May 2025
PRINCETON JUNCTION, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, May 8, 2025, at 9:00 am Eastern Standard Time to present its res
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
01:42pm, Wednesday, 30'th Apr 2025
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK a
MISTRAS Group Launches MISTRAS Data Solutions Brand, Integrating Data-driven Capabilities for Customers Worldwide
08:00am, Thursday, 24'th Apr 2025
PRINCETON JUNCTION, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), the leading global provider of integrated, technology-enabled asset protection solutions, today announced t
MISTRAS Group Names Aerospace & Defense Leader Cliff Schaffer as SVP of In-Lab Services
08:30am, Monday, 14'th Apr 2025
PRINCETON JUNCTION, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), the leading provider of integrated technology-enabled asset protection solutions, today announced the appoi
MISTRAS Group Rings Bell at NYSE, Reaffirming Its Leadership in Data-Driven Asset Protection
08:00am, Wednesday, 09'th Apr 2025
PRINCETON JUNCTION, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), the leading “one source” multinational provider of integrated technology-enabled asset protection solut
Mistras (MG) Surges 5.7%: Is This an Indication of Further Gains?
12:10pm, Monday, 24'th Mar 2025
Mistras (MG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announce
